Drug Profile
Interferon beta 1a - Faron Pharmaceuticals
Alternative Names: FP-1201; FP-1201-lyo; IFN beta-1a; Interferon beta-1a - Faron Pharmaceuticals; MR11A8; Recombinant human interferon beta-1a - Faron Pharmaceuticals; TraumakineLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Faron Pharmaceuticals
- Developer Faron Pharmaceuticals; Maruishi Pharmaceutical
- Class Antiasthmatics; Antineoplastics; Antivirals; Interferons; Vascular disorder therapies
- Mechanism of Action Immunostimulants; Interferon beta-1a replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Adult respiratory distress syndrome
Highest Development Phases
- Preclinical Acute kidney injury; Cytokine release syndrome; Reperfusion injury
- No development reported Vascular injuries
- Discontinued Abdominal aortic aneurysm; Adult respiratory distress syndrome; Brain injuries; Spinal cord injuries
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Vascular injuries(Prevention) in Finland (IV)
- 10 Jul 2023 Faron Pharmaceuticals plans a phase I/II trial for Cytokine release syndrome (Prevention, In adults, In the elderly) in the US (IV) (NCT05936229)
- 05 May 2022 Faron Pharmaceuticals terminates the phase-II/III trial HIBISCUS in Adult respiratory distress syndrome (In COVID-2019 patients) in USA, due to shift in pandemic of COVID-2019 infections which caused slow accrual of patients (IV) (NCT04860518)